Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 2 Discriminatory antibodies for CD4+ T cellsa

From: Antibody microarray analysis of cell surface antigens on CD4+ and CD8+ T cells from HIV+ individuals correlates with disease stages

Discriminatory Antibody Up(+)/Down(-) P Value
BDL vs. NEG   
CD11b + 0.0599
CD95 + 0.0619
CD45RA - 0.0679
LTNP vs. NEG   
CD71 + 0.0151
CD 212 b1 + 0.0307
HLA-DR + 0.0312
CD27 PH - 0.0560
CD11b + 0.0589
CD95 + 0.0752
VIR vs. NEG   
CD71 + 0.0032
CD11b + 0.0227
CD57 + 0.0307
CD95 + 0.0349
CD28 - 0.0540
CD218a + 0.0732
CD86 + 0.0744
BDL vs. LTNP   
CD183 - 0.0105
HLA-DR - 0.0270
CD38 - 0.0316
CD71 - 0.0385
CD218a - 0.0470
CD212 b1 - 0.0687
CD54 - 0.0695
VIR vs. LTNP   
CD183 - 0.0451
CD3epsilon - 0.0489
CD27 PH + 0.0829
VIR vs. BDL   
CD71 + 0.0195
CD218a + 0.0355
CD54 + 0.0421
  1. aSix paired comparisons of CD markers on CD4+ cells providing significant discrimination between patient groups, with relative changes in CD antigen binding in the former vs. the latter denoted by "+" and "-" to indicate increase and decrease, respectively. Antigens that did not achieve statistical significance (p > 0.05) but have been previously reported in HIV disease context or have been found to be significant in other pair comparisons are also shown in italic. The "PH" in CD27 PH distinguishes this Pharmingen antibody (clone M-T271) from the Immunotech antibody 27 IM (clone 1A4-CD27).